Home About us Contact
|
Home About us Contact | ||
|
|
||
Recurrent Group (recurrent + group)
Selected AbstractsEfficacy of Tonsillectomy in Treatment of Recurrent Group A ,-Hemolytic Streptococcal PharyngitisTHE LARYNGOSCOPE, Issue 11 2006Laura J. Orvidas MD Abstract Objective: The objective of this study was to determine whether children with tonsillectomies experienced fewer recurrent group A ,-hemolytic streptococcal (GABHS) infections after surgery compared with children who did not receive tonsillectomies. Study Design/Methods: The authors conducted a retrospective cohort study of 290 children 4 to <16 years who experienced three or more episodes of group A ,-hemolytic streptococcal pharyngitis at least 1 month apart in 12 months. Results: Children without tonsillectomy were 3.1 times (95% confidence interval, 1.9,4.9; P < .001) more likely to develop a subsequent group A ,-hemolytic streptococcal pharyngitis infection during follow up than children who underwent tonsillectomy after adjusting for the number of group A ,-hemolytic streptococcal pharyngitis infections per patient within the previous year and the presence of preexisting conditions. Among the children who developed a subsequent group A ,-hemolytic streptococcal pharyngitis infection, the children without a tonsillectomy developed a group A ,-hemolytic streptococcal pharyngeal infection sooner (median, 0.6 vs. 1.1 years). Conclusions: Tonsillectomy is associated with a decrease in the number of group A ,-hemolytic streptococcal pharyngitis infections in children with a history of recurrent groups A ,-hemolytic streptococcal pharyngitis infection. Tonsillectomy also increased the amount of time before development of further GABHS pharyngitis. [source] Microendoscopic discectomy for recurrent lumbar disc herniation*ASIAN JOURNAL OF ENDOSCOPIC SURGERY, Issue 2 2010M Matsumoto Abstract Introduction: The purpose of this study is to elucidate the feasibility of microendoscopic discectomy (MED) for the treatment of recurrent lumbar disc herniation. Methods: Thirty-six patients with recurrent lumbar disc herniation were treated using MED (30 men and six women; mean age: 45.7 years, range: 26,80 years; mean follow-up: 24.4 months, range: 12,52 months; mean duration between the primary and revision surgery: 65.9 months, range: 1,320 months) (recurrent group). Sex- and age-matched patients with primary lumbar disc herniation treated by MED served as the control group (primary group). The clinical outcomes were evaluated using the Japanese Orthopaedic Association score for low back pain and questionnaires regarding MED. Results: The average Japanese Orthopaedic Association scores before surgery and at the final follow-up were significantly lower in the recurrent group than in the primary group (10.8 ± 3.4 versus 15.0 ± 4.0 before surgery, P=0.001 and 25.4 ± 2.6 versus 26.8 ± 1.9 at follow-up, P=0.013), while the average recovery rates were not significantly different between the two groups (80.3 ± 14.1% versus 84.5 ± 14.6, P=0.22). The surgical time was significantly longer for the recurrent group than for the primary group (83.0 ± 41.8 min versus 67.1 ± 18.1 min,P=0.042). Of the 18 questionnaire respondents, 17 answered that postoperative pain was milder after MED than after a standard discectomy. Conclusion: MED is a feasible surgical option for recurrent lumbar disc herniation, yielding surgical outcomes comparable to those obtained in primary lumbar disc herniation. [source] Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid glandCANCER, Issue 8 2002Afina S. Glas M.D. Abstract BACKGROUND Patients with recurrent pleomorphic adenomas of the parotid gland are difficult to manage without considerable risk of facial nerve injury. The prognostic significance of progesterone receptor (PR) and estrogen receptor (ER) reported in these adenomas was evaluated in patients with recurrent pleomorphic adenomas, comparing the results in a group of patients with primary adenomas without recurrences during 10 years of follow-up. METHODS Paraffin embedded tumor samples from 52 patients with recurrent pleomorphic adenoma of the parotid gland were collected and stained immunohistochemically. Expression of PR, ER, Ki-67 antigen, and insulin-like growth factor receptor-1 (IGFR-1) was analyzed in resected samples of recurrent tumors and was compared with samples from a control group of patients with primary pleomorphic adenoma. RESULTS A difference (P < 0.05) in the type of tumor was observed between the recurrent group (more cell-poor variants) and the control group. ER expression was low in both groups (19% and 17%, respectively), but immunoreactivity for ER was higher (48%) in normal parotid gland tissue. PR expression in the recurrent group (96%) was higher compared with PR expression in the control group (61%; P < 0.001). PR expression and IGFR-1 expression were correlated weakly (correlation coefficient = 0.660; P = 0.053) in the recurrent group. The expression of growth fraction (Ki-67 score) and IGFR-1 was similar in both groups but was more extensive compared with normal parotid gland tissue. CONCLUSIONS PR seems to be a prognostic factor in recurrent pleomorphic adenoma of the parotid gland. The PR pathway can be considered a potential target for hormone treatment in patients with these recurrent adenomas. Cancer 2002;94:2211,16. © 2002 American Cancer Society. DOI 10.1002/cncr.10445 [source] The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomasCELL PROLIFERATION, Issue 1 2005L. Maes However, a number of these tumours recur even after total resection. The aim of this study is to evaluate the prognostic significance for recurrence of the human telomerase catalytic subunit (hTERT) in the cells of meningiomas. The expression of hTERT-protein can be evaluated by immunohistochemical staining using a monoclonal antibody against hTERT (clone 44F42, NCL-L-hTERT). The interdependence between tumour recurrence and cell proliferation in this study is analysed by Ki-67 immunoreactivity (clone MIB-1). Archival material from 29 non-recurrent and 32 recurrent tumours has been evaluated, including specimens from World Health Organization (WHO) stages I (n = 73), II (n = 2) and III (n = 12). Although the tumours were categorized as benign meningiomas following the WHO classification, recurrence in 22 of 50 cases did not correlate with the tumour stage. For hTERT staining, the following results were found for nucleolar and total nuclear staining, respectively: non-recurrent meningiomas, 2.9% (± 7.7) and 3.0% (± 8.0); recurrent meningiomas at first resection, 16.8% (± 19.7) and 31.6% (± 30.2). Concerning the Ki-67 labelling index (LI): for the group of non-recurrent meningiomas, results were 2.1% (± 1.7) and for the recurrent group at first resection, 1.7% (± 2.0). A significant difference was seen for the hTERT staining (P < 0.001) between the non-recurrent and recurrent meningiomas, whereas no statistical significance was found for Ki-67. In conclusion hTERT-positive meningiomas had a high incidence for recurrence. Ki-67 was a good marker of cell proliferation status of the tumours, but did not correlate with recurrence; thus, hTERT alone seemed to be a potential predictor for recurrence. [source] | ||||||||||